The health and well-being sectors are of vital importance and continue to evolve. Advances in nanotechnology, genetic mapping and medical devices are opening up new opportunities for industry players, while improving peoples’ lives around the world. McMillan’s life sciences lawyers represent clients in both the private and public sector in the biotechnology, pharmaceuticals and healthcare industries. We understand the challenges and opportunities that life science law presents.
As a top healthcare and life sciences law firm, McMillan LLP employs strategic legal counsel to help our clients meet the industry’s challenges head-on while positioning them to profitably bring innovations to the market. With our integrated approach, we can deliver comprehensive, customized legal solutions in the most challenging circumstances.
Public institutions and private enterprises operating in the complex healthcare sector require the services of healthcare lawyers who understand both the challenges and opportunities of the industry.
By combining a passion for healthcare and significant industry experience, McMillan lawyers provide clients with practical and relevant legal advice. We work with North America’s leading hospitals, managed care companies, clinics and laboratories, as well as investors, insurers, lenders and venture capital involved in the industry.
Among the ways McMillan works with clients are through advising on the latest healthcare legislation, reimbursement regulations, and director and officer obligations; representing healthcare professionals in disciplinary matters; negotiating service contracts with third-party providers, facilities and joint ventures; advising on mergers, acquisitions and divestitures; representing healthcare professionals in dispute resolution and litigation, including class actions; and advising on tax and privacy matters
The pharmaceutical industry combines the business and science of the healthcare sector. Drugs can take many years and millions of dollars in research and development costs to bring to market. Though challenging, pharmaceutical development is also rewarding. McMillan lawyers understand the process of developing, testing and marketing pharmaceutical products. We combine a thorough knowledge of healthcare laws and regulations with a passion for helping clients bring life-saving and life-enhancing drugs to market.
McMillan’s life sciences industry lawyers work with clients to advise on patent and trademark matters; represent them in intellectual property litigation; assist with mergers, acquisitions and divestiture; structure financing arrangements through private equity, public markets and venture capital; advise on drug pricing and reimbursement strategies; assist with regulatory approvals; draft clinical trial, licensing and collaboration, and supply, manufacturing and distribution agreements; advise on labelling, advertising and distribution matters; represent them in product liability litigation and class actions; and advise on tax matters.
Biotechnology is a complex business that faces many challenges to bring their products to market profitably. Government regulation, intellectual property issues and securing financing all require expert Biotech lawyers and expert industry awareness.
At McMillan, our lawyers combine strong industry expertise in Biotech law with vital knowledge of the legal and regulatory environments that impact the industry. By using a multidisciplinary approach, we provide Biotech companies with effective solutions so that they can continue to develop life-saving and life-enhancing advances.
Among the ways McMillan lawyers assist biotech clients is with intellectual property issues, such as patents, trademarks, licensing, outsourcing and strategic alliances; advising on regulatory issues concerning sales and marketing, pricing, privacy, research and development processes, competition and trade; structuring public and private corporate finance, mergers, acquisitions and divestitures; negotiating government contracts; representing them in litigation proceedings related to product liability, commercial disputes, consumer class actions and intellectual property; and advising on research tax incentives.
Insights (10 Posts)View More
It is now clear: the revised preferability analysis under the amended Class Proceedings Act is a strict, more onerous hurdle for plaintiffs to satisfy.
This is an overview of the Industrial Design Regime in Canada
New proposed changes to Investment Canada Act include significant new rules for state-owned enterprises, asset acquisitions, and net-benefit test.
CIPO's new standard fees come into effect on January 1, 2024. Plan ahead; save on government fees.
The Canadian Federal Court reaffirms that limitation periods do not apply to declarations made under Section 52 of the Patent Act.
Glencore plc’s recent approaches to the shareholders of Teck Resources has once again brought the Investment Canada Act into the spotlight.
Canada imposes new reporting obligations on forced labour, and what it means for Canadian businesses.
Last Minute Fine Tuning – Québec Government Tries to Soften the Blow of Some of the More Far-Reaching Requirements Under Bill 96, as Applicable to Government Interactions
Entry into force of the Regulation respecting the language of the civil administration and the Regulation respecting the derogations to the duty of exemplarity
Psychedelics have come to be viewed as a potential therapeutic tool by the general public and government. This bulletin summarizes recent Canadian developments.
Alberta is implementing a new framework for regulating and licensing health care providers in connection with administering psychedelics.
Get updates delivered right to your inbox. You can unsubscribe at any time.